🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

117 results for “Sanofi Pharma Bristol-Myers Squibb” Clear

  1. same excipients except no hypromellose, PREDNISONE , SAR445761 - belumosudil, PREDNISOLONE

    Sanofi Pharma Bristol-Myers Squibb

    chronic graft versus host disease

    phase 3 small molecule active

    1 trial

  2. A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy

    Sanofi Pharma Bristol-Myers Squibb

    Type 1 diabetes mellitus

    phase 2 other active

    1 trial

  3. A parallel-group treatment, Phase 2a, multicenter, randomized, double-blind, placebo-controlled umbrella study to evaluate the efficacy and safety of frexalimab, brivekimig and rilzabrutinib in participants aged 16 to 75 years with primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD)

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 2 other active

    1 trial

  4. A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa

    Sanofi Pharma Bristol-Myers Squibb

    Hidradenitis suppurativa

    phase 2 other active

    1 trial

  5. A study in two groups of healthy male adult participants to assess how much test medicine (SAR441566) is taken up, degraded and removed by the body and to assess the extent to which SAR441566 becomes available to the body when given by mouth

    Sanofi Pharma Bristol-Myers Squibb

    Healthy volunteers

    phase 2 other active

    1 trial

  6. Amlitelimab, Amlitelimab matching placebo comprised of the same excipients as the Test product without the active substance

    Sanofi Pharma Bristol-Myers Squibb

    Hidradenitis

    phase 2 small molecule active

    1 trial

  7. Amlitelimab, Amlitelimab matching placebo to test product

    Sanofi Pharma Bristol-Myers Squibb

    Coeliac disease

    phase 2 small molecule active

    1 trial

  8. Amlitelimab, Amlitelimab matching placebo to test product

    Sanofi Pharma Bristol-Myers Squibb

    Alopecia areata

    phase 2 small molecule active

    1 trial

  9. Amlitelimab, Placebo

    Sanofi Pharma Bristol-Myers Squibb

    Asthma

    phase 2 small molecule active

    1 trial

  10. An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301

    Sanofi Pharma Bristol-Myers Squibb

    Asthma

    phase 2 other active

    1 trial

  11. Balinatunfib, Not the same excipients as test

    Sanofi Pharma Bristol-Myers Squibb

    Crohn's disease, Colitis Ulcerative

    phase 2 small molecule active

    1 trial

  12. Dexamethason 4 mg JENAPHARM®, evorpacept, Isatuximab, Dexamethason 8 mg JENAPHARM®, Isatuximab

    Sanofi Pharma Bristol-Myers Squibb

    Cancer

    phase 2 small molecule active

    1 trial

  13. Dexamethason 8 mg JENAPHARM®, SAR445761 - belumosudil, Isatuximab, Isatuximab, Dexamethason 4 mg JENAPHARM®

    Sanofi Pharma Bristol-Myers Squibb

    Cancer

    phase 2 small molecule active

    1 trial

  14. Frexalimab, Matched Placebo for Test

    Sanofi Pharma Bristol-Myers Squibb

    Systemic lupus erythematosus

    phase 2 small molecule active

    1 trial

  15. Hexyon suspension for injection in pre-filled syringe Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)., MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, RotaTeq oral solution Rotavirus vaccine (live), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), MenPenta SD, Prevenar 13 suspension for in

    Sanofi Pharma Bristol-Myers Squibb

    Meningococcal immunization

    phase 2 small molecule active

    1 trial

  16. INBRX-101 Concentrate for Solution for Infusion 50mg/ml

    Sanofi Pharma Bristol-Myers Squibb

    Alpha-1 Antitrypsin Deficiency (AATD) Emphysema

    phase 2 small molecule active

    1 trial

  17. Imnovid 4 mg hard capsules, JAMP Pomalidomide, Pomalidomide Adalvo 3 mg hard capsules, Imnovid 1 mg hard capsules, Imnovid 4 mg hard capsules, Pomalidomide Adalvo 1 mg hard capsules, Imnovid 2 mg hard capsules, JAMP Pomalidomide, Imnovid 1 mg hard capsules, JAMP Pomalidomide, Dexamethason 4 mg JENAPHARM®, Imnovid 3 mg hard capsules, Pomalidomide Adalvo 4 mg hard capsules, Pomalidomide Adalvo 2 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Isatuximab, Isatuximab, JAMP Pomalidomide, Imnovid 3 mg hard capsul

    Sanofi Pharma Bristol-Myers Squibb

    Cancer

    phase 2 small molecule active

    1 trial

  18. Isatuximab, Dexamethason 8 mg JENAPHARM®, Dexamethason 4 mg JENAPHARM®, Isatuximab

    Sanofi Pharma Bristol-Myers Squibb

    Cancer

    phase 2 small molecule active

    1 trial

  19. Isatuximab, Kyprolis 60 mg powder for solution for infusion, METHYLPREDNISOLONE , MONTELUKAST , DexaGalen® 8 mg injekt Injektionslösung, DIPHENHYDRAMINE , Dexamethason 4 mg JENAPHARM®, Dr. Reddy's Carfilzomib, PARACETAMOL

    Sanofi Pharma Bristol-Myers Squibb

    Cancer - Relapsed/refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  20. Itepekimab

    Sanofi Pharma Bristol-Myers Squibb

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule active

    1 trial

  21. Itepekimab, Matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Bronchiectasis

    phase 2 small molecule active

    1 trial

  22. Match Placebo to Test Product, SAR441566, SAR441566

    Sanofi Pharma Bristol-Myers Squibb

    Psoriasis

    phase 2 small molecule active

    1 trial

  23. Match placebo to test product, Balinatunfib

    Sanofi Pharma Bristol-Myers Squibb

    Crohn's disease

    phase 2 small molecule active

    1 trial

  24. Match placebo to test product, METHOTREXATE , SAR441566, SAR441566

    Sanofi Pharma Bristol-Myers Squibb

    Rheumatoid arthritis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources